Dabigatranetexilat Towa Pharmaceutical Europe

Dabigatran Etexilate is an oral medication used to prevent blood clots. Manufactured by Towa Pharmaceutical Europe, it is commonly prescribed for conditions requiring anticoagulation therapy.

Dabigatran Etexilate is primarily used to reduce the risk of blood clots forming in the body. It is often prescribed for conditions such as atrial fibrillation, where clots can lead to strokes, and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). This medication works by inhibiting a specific clotting factor, helping to keep blood flowing smoothly through the vessels.

Common effects of Dabigatran Etexilate may include mild bleeding, such as nosebleeds or bruising. Some users might experience stomach pain, heartburn, or indigestion. Severe bleeding, though rare, can occur and should be reported to a healthcare provider immediately.

Dabigatran Etexilate should be handled with care, especially by individuals with a history of bleeding disorders or stomach ulcers. It is important to follow the prescribed dosage and to inform healthcare providers about any other medications being taken. Regular monitoring may be necessary to ensure the medication is working as intended.

Dabigatran Etexilate can interact with various medications, including other blood thinners, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain antibiotics. Alcohol consumption should be moderated, as it can increase the risk of bleeding. Always consult a healthcare provider before starting or stopping any medication while on Dabigatran Etexilate.